Project Details
Description
PROJECT SUMMARY
TMJ osteoarthritis (OA) poses a major clinical problem, but there are no therapies that promote TMJ
regeneration. Therapeutically exploiting resident stem cells represents a stem cell-based strategy for tissue
regeneration. We have identified TMJ fibrocartilage stem cells (FCSCs) localized within the TMJ condyle
superficial zone. Transplanted FCSCs engraft, self-organize and regenerate cartilage, fat and vascularized
bone. FCSCs are heterogeneous, yet markers critical for studying signals regulating FCSCs are unknown. We
found that Prg4+, Lgr5+ and Prg4+Lgr5+ cells represent FCSC populations in rodents and pigs. We discovered
that Wnt/βCatenin signaling is critical for FCSC fate specification by inducing proliferation and inhibiting
differentiation of FCSCs. However, over-active Wnt/βCatenin is associated with TMJ OA. We developed two
TMJ disease models in mice and pigs and discovered that TMJ OA is correlated with increased βCatenin and
apoptosis mediated FCSC depletion. These data suggest inhibition of Wnt/βCatenin may serve as a
therapeutic regenerative strategy for the treatment of TMJ OA. In fact, we show that therapeutic application of
a canonical Wnt inhibitor repairs TMJ in a rabbit TMJ injury model. Based on our published work and
preliminary data, we hypothesize that Prg4+, Lgr5+ and Prg4+Lgr5+ are FCSCs and Wnt/βCatenin inhibition in
FCSCs regenerates TMJ. We will test our hypothesis using three specific aims: 1) Define FCSC populations
critical for TMJ development and homeostasis; 2) Determine the role of Wnt/βCatenin signaling in regulating
FCSC fate; 3) Target resident FCSCs to regenerate cartilage in a porcine TMJ injury model. Using mouse
genetics, we will characterize FCSCs and delineate the role of Wnt/βCatenin signaling in regulating FCSC fate.
We will optimize a new, clinically relevant large animal model and test Wnt inhibition in FCSCs as a potential
therapy for TMJ OA. Taken together, these novel studies will contribute towards the development of a non-
surgical, minimally invasive stem cell-based therapy for TMJ regeneration.
Status | Finished |
---|---|
Effective start/end date | 7/15/19 → 4/30/23 |
Funding
- National Institute of Dental and Craniofacial Research: US$715,349.00
- National Institute of Dental and Craniofacial Research: US$708,196.00
ASJC Scopus Subject Areas
- Biotechnology
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.